AMYLIN PHARMACEUTICALS INC (AMLN) [Rocket]

Overview

AMYLIN PHARMACEUTICALS INC (AMLN)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/22/2012	EFFECT	Form EFFECT - Notice of Effectiveness
08/21/2012	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]
08/20/2012	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
08/20/2012	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
08/20/2012	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
08/20/2012	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
08/20/2012	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-11	Dec-31-10	Dec-31-09	Dec-31-08	Dec-31-07	Dec-31-06	Dec-31-05	Dec-31-04
Revenues	650.7	668.8	758.4	769.6	720.7	510.9	140.5	34.3
Revenue growth	-2.7%	-11.8%	-1.5%	6.8%	41.1%	263.7%	309.9%	-60.0%
Cost of goods sold	48.4	61.7	83.0	91.6	65.5	50.1	14.8	0.0
Gross profit	602.3	607.1	675.4	678.0	655.3	460.8	125.7	34.3
Gross margin	92.6%	90.8%	89.1%	88.1%	90.9%	90.2%	89.5%	100.0%
Selling, general and administrative	271.2	276.9	330.5	395.1	391.0	282.0	171.5	67.0
Research and development	161.2	183.1	198.4	222.6	216.3	222.1	132.1	119.6
EBITA	-464.6	-110.0	-156.4	-242.3	-243.0	-237.4	-209.3	-152.2
EBITA margin	-71.4%	-16.4%	-20.6%	-31.5%	-33.7%	-46.5%	-149.0%	-444.3%
Amortization of intangibles	4.0
EBIT	-468.6	-110.0	-156.4	-242.3	-243.0	-237.4	-209.3	-152.2
EBIT margin	-72.0%	-16.4%	-20.6%	-31.5%	-33.7%	-46.5%	-149.0%	-444.3%
Pre-tax income	0.0	0.0	0.0	0.0	-216.5	-218.9	-206.8	-157.2
Income taxes	0.1	-0.5	-2.0	0.0	0.0	0.0	0.0	0.0
Tax rate					0.0%	0.0%	0.0%	0.0%
Net income	-543.4	-152.3	-186.3	-321.9	-216.5	-218.9	-206.8	-157.2
Net margin	-83.5%	-22.8%	-24.6%	-41.8%	-30.0%	-42.8%	-147.2%	-458.6%

Diluted EPS	($3.73)	($1.06)	($1.32)	($2.35)	($1.63)	($1.78)	($1.96)	($1.67)
Shares outstanding (diluted)	145.7	143.5	140.7	137.0	132.6	122.6	105.5	94.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.